Children with juvenile idiopathic arthritis have a risk 2-3 times more likely to develop than children of the same age without AIG, according to a study presented this week at a meeting of the American College of Rheumatology Annual Scientific Atlanta. The same study reported no cases of cancer in children with juvenile idiopathic arthritis, who were exposed to anti-TNF.I think most people agree that there is a greater risk [of cancer in patients with juvenile idiopathic arthritis], but not all attributable to TNF blockers. At least in part the increased risk, and perhaps all, seems to be due the disease itself, says Dr. Beukelman.
About one child in 1000 develops a certain type of juvenile arthritis. These disorders can affect children at any age, although rarely in the first six months of life. An estimated 300,000 children in the United States were diagnosed with JIA. There are different types of AIG, which involves all the chronic inflammation of the joints.
These fibers have properties (elasticity, solubility, etc. The model proposed by the team could also help to understand the genesis and development of these diseases.
TNF antagonists, also known as biological anti-TNF, are a class of drugs that have been used since 1998 and together have given more than 600,000 people around the world. These drugs are administered by injection to reduce inflammation by interfering with biological substances that cause or aggravate the inflammatory process.
There have been few studies on the relationship between AJI and cancer. However, efforts to establish the background risk of cancer associated with JIA have increased since the FDA issued its findings that the TNF inhibitors are associated with an increased risk of cancer. Efforts are also underway to collect data prospectively on all children who are exposed to TNF blockers.
How activity affects cancer risk of the disease is unknown AIG. We have not had access to such information in the administrative clinical database, says Dr. Beukelman.